Glaukos Corporation (GKOS): Price and Financial Metrics

Glaukos Corporation (GKOS): $75.55

0.65 (-0.85%)

POWR Rating

Component Grades








GKOS Price/Volume Stats

Current price $75.55 52-week high $80.28
Prev. close $76.20 52-week low $40.45
Day low $75.55 Volume 6,581
Day high $76.26 Avg. volume 435,181
50-day MA $75.04 Dividend yield N/A
200-day MA $59.16 Market Cap 3.68B

GKOS Stock Price Chart Interactive Chart >


  • GKOS scores best on the Growth dimension, with a Growth rank ahead of 61.52% of US stocks.
  • The strongest trend for GKOS is in Value, which has been heading down over the past 177 days.
  • GKOS's current lowest rank is in the Momentum metric (where it is better than 6.97% of US stocks).

GKOS Stock Summary

  • With a price/sales ratio of 12.34, GLAUKOS CORP has a higher such ratio than 92.09% of stocks in our set.
  • Over the past twelve months, GKOS has reported earnings growth of 164.76%, putting it ahead of 91.87% of US stocks in our set.
  • The volatility of GLAUKOS CORP's share price is greater than that of 73.62% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to GLAUKOS CORP are AAOI, GPRO, SONO, NSPR, and KALA.
  • Visit GKOS's SEC page to see the company's official filings. To visit the company's web site, go to

GKOS Valuation Summary

  • GKOS's price/sales ratio is 12.3; this is 547.37% higher than that of the median Healthcare stock.
  • GKOS's price/earnings ratio has moved up 80.4 over the prior 100 months.

Below are key valuation metrics over time for GKOS.

Stock Date P/S P/B P/E EV/EBIT
GKOS 2023-09-22 12.3 7.5 -29.0 -35.4
GKOS 2023-09-21 12.3 7.5 -28.9 -35.4
GKOS 2023-09-20 12.4 7.5 -29.1 -35.6
GKOS 2023-09-19 12.6 7.6 -29.5 -36.0
GKOS 2023-09-18 12.4 7.5 -29.1 -35.5
GKOS 2023-09-15 12.3 7.5 -28.9 -35.3

GKOS Growth Metrics

    The 3 year revenue growth rate now stands at 50.5%.
  • Its 5 year revenue growth rate is now at 87.32%.
  • The 3 year net income to common stockholders growth rate now stands at -139.57%.
Over the past 49 months, GKOS's revenue has gone up $116,023,000.

The table below shows GKOS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 284.875 -33.598 -89.607
2022-06-30 288.316 10.707 -55.801
2022-03-31 293.724 30.304 -27.747
2021-12-31 294.011 24.708 -49.593
2021-09-30 294.005 39.963 -38.369
2021-06-30 284.126 12.603 -60.347

GKOS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • GKOS has a Quality Grade of C, ranking ahead of 54.76% of graded US stocks.
  • GKOS's asset turnover comes in at 0.279 -- ranking 135th of 186 Medical Equipment stocks.
  • FONR, ATRC, and BSX are the stocks whose asset turnover ratios are most correlated with GKOS.

The table below shows GKOS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.279 0.747 -0.076
2021-03-31 0.236 0.681 -0.129
2020-12-31 0.238 0.592 -0.218
2020-09-30 0.243 0.595 -0.310
2020-06-30 0.291 0.632 -0.400
2020-03-31 0.432 0.731 -0.328

Glaukos Corporation (GKOS) Company Bio

Glaukos Corporation develops and commercializes products and procedures designed for the treatment of glaucoma. The company was founded in 1998 and is based in Laguna Hills, California.

GKOS Latest News Stream

Event/Time News Detail
Loading, please wait...

GKOS Latest Social Stream

Loading social stream, please wait...

View Full GKOS Social Stream

Latest GKOS News From Around the Web

Below are the latest news stories about GLAUKOS CORP that investors may wish to consider to help them evaluate GKOS as an investment opportunity.

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

Sector ETF report for PSCH

Yahoo | September 19, 2023

Glaukos Announces Participation in Wells Fargo Healthcare Conference

ALISO VIEJO, Calif., August 23, 2023--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 6, 2023, at 12:45 p.m. ET in Boston, MA.

Yahoo | August 23, 2023

Glaukos (GKOS) Q2 Earnings Beat Estimates, Revenues Rise Y/Y

Glaukos' (GKOS) second-quarter revenues beat estimates but fall year over year. Sales and gross margin improve, while higher operating expenses lead to a wider operating loss.

Yahoo | August 3, 2023

Compared to Estimates, Glaukos (GKOS) Q2 Earnings: A Look at Key Metrics

The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Yahoo | August 3, 2023

Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates

Glaukos (GKOS) delivered earnings and revenue surprises of 3.51% and 7.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 2, 2023

Read More 'GKOS' Stories Here

GKOS Price Returns

1-mo -0.21%
3-mo 6.09%
6-mo 50.80%
1-year 41.14%
3-year 48.22%
5-year 16.41%
YTD 72.96%
2022 -1.71%
2021 -40.95%
2020 38.17%
2019 -3.03%
2018 118.99%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!